Digital Health
DiagnaMed Expects Brain Health AI Platform To Be Commercialized In Q4 2023
DiagnaMed Holdings (CSE: DMED) is anticipating to begin the commercialization stage of its flagship CERVAI brain health AI platform in the fourth quarter…
FULL DISCLOSURE: This is sponsored content for DiagnaMed Holdings.
DiagnaMed Holdings (CSE: DMED) is anticipating to begin the commercialization stage of its flagship CERVAI brain health AI platform in the fourth quarter of 2023.
The timeline estimate was provided by the company in an announcement this morning, which indicated that they expect the tool to be available at health centers, pharmacies, hospitals, clinics, doctors offices, and homes. Commercial support tools are in the process of being finalized, while discussions with clinics and research centres across North America are currently underway.
The platform currently consists of a Brain Age Estimation as well as a Brain Health Assessment tool, the latter of which includes an electroencephalogram headset and machine-learning model. The assessment tool generates a brain health score and clinician-observed measures to enable users to be proactive with their brain health. The mHealth & eHealth Development and Innovation Centre was reportedly hired to integrate the assessment service of CERVAI into what is recognized as Canada’s Digital Health Technology Access Centre.
READ: DiagnaMed Launches Dr. GenAI, A Generative AI Medical Chatbot
The current Brain Age model meanwhile predicts chronological ages with a medium-to-strong statistical effect size based on EEG data recorded from the headset, the data from which is then processed using a proprietary machine-learning model. The final phase of development of the Brain Age program is said to be complete, with final results from the clinic and home studies slated to be published later this year to support commercialization.
“We are in the final stage of development for CERVAI, our novel brain health AI platform. We expect to launch CERVAI in Q4-2023. CERVAI is for people who want to take control of their brain health,” commented CEO Fabio Chianelli.
DiagnaMed Holdings last traded at $0.04 on the CSE.
FULL DISCLOSURE: DiagnaMed Holdings is a client of Canacom Group, the parent company of The Deep Dive. Canacom Group is currently long the equity of DiagnaMed Holdings. The author has been compensated to cover DiagnaMed Holdings on The Deep Dive, with The Deep Dive having full editorial control. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security.
The post DiagnaMed Expects Brain Health AI Platform To Be Commercialized In Q4 2023 appeared first on the deep dive.
Keep it Short
By KIM BELLARD OK, I admit it: I’m on Facebook. I still use Twitter – whoops, I mean X. I have an Instagram account but don’t think I’ve ever posted….
Asian Fund for Cancer Research announces Degron Therapeutics as the 2023 BRACE Award Venture Competition Winner
The Asian Fund for Cancer Research (AFCR) is pleased to announce that Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition….
Seattle startup Olamedi building platform to automate health clinic communications
A new Seattle startup led by co-founders with experience in health tech is aiming to automate communication processes for healthcare clinics with its software…
